TREATMENT GUIDE |
SilDerm Scar Gel & Spray SilDerm™ Limited
TM
Description Both the Scar Gel and Spray work by bonding to the outer layer of the skin, providing a protective barrier against chemical, physical, and microbial contamination of the scar site. The gel and the spray both dry quickly to form an ultra-thin, breathable, waterproof silicone membrane that allows the scar to heal naturally through normal collagen synthesis. This also normalises the over production of collagen, which can lead to abnormal scars. Apply twice-daily to reduce scar redness, decrease scar volume, and reduce pain and itchiness. The unique blend of naturally occurring silicones has been proven in clinical studies to flatten, soften, and smooth scar tissue. This silicone also dramatically reduces the redness and relieves the itching and discomfort often associated with scars.
Indications Scar tissue Contact
www.silderm.com
combination of TAC (40 mg/ml) : 5FU
(50 mg/ml) (1:9 to 1:3), demonstrating superior results with regard to reduction in keloid size and redness16
. For further Surgical excision of
keloids without adjuvant therapy, such as post- excisional corticosteroid injections, 5-fluorouracil, or radiation is associated with high recurrence rates and should thus be considered with immense caution.
aesthetic improvement, a PDL may be used to decrease erythema and potential teleangiectasia. Based on the currently
References
1. Nast A, Eming S, Fluhr J et al. German S2k guidelines for the therapy of pathological scars (hypertrophic scars and keloids). J Dtsch Dermatol Ges 2012; 10(10): 747–62
2. O’Brien L, Pandit A. Silicon gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Database Syst Rev 2006; (1): CD003826
3. Bianchi FA, Roccia F, Fiorini P, Berrone S. Use of Patient and Observer Scar Assessment Scale for evaluation of facial scars treated with self-drying silicone gel. J Craniofac Surg 2010; 21(3): 719–23
4. van der Wal MB, van Zuijlen PP, van de Ven P, Middelkoop E. Topical silicone gel versus placebo in promoting the maturation of burn scars: a randomized controlled trial. Plast Reconstr Surg 2010; 126(2): 524–31
78 ❚
5. Steinstraesser L, Flak E, Witte B, et al. Pressure garment therapy alone and in combination with silicone for the prevention of hypertrophic scarring: randomized controlled trial with intraindividual comparison. Plast Reconstr Surg 2011; 128(4): 306–13
6. Chernoff WG, Cramer H, Su-Huang S. The efficacy of topical silicone gel elastomers in the treatment of hypertrophic scars, keloid scars, and post-laser exfoliation erythema. Aesthetic plast surg 2007; 31(5): 495–500
7. Stoffels I, Wolter TP, Sailer AM, Pallua N. [The impact of silicone spray on scar formation. A single-center placebo- controlled double-blind trial]. Hautarzt 2010; 61(4): 332–8
8. Mustoe TA, Cooter RD, Gold MH, et al. International clinical recommendations on
scar management. Plast Reconstr Surg 2002; 110(2): 560–71
9. Jalali M, Bayat A. Current use of steroids in management of abnormal raised skin scars. Surgeon 2007; 5(3): 175–80
10. Tredget EE, Nedelec B, Scott PG, Ghahary A. Hypertrophic scars, keloids, and contractures. The cellular and molecular basis for therapy. Surg Clin North Am 1997; 77(3): 701–30
11. Murray JC. Keloids and hypertrophic scars. Clin Dermatol 1994; 12: 27–37
12. Lawrence WT. In search of the optimal treatment of keloids: report of a series and a review of the literature. Ann Plast Surg 1991; 27(2): 164–78
13. Alster TS, Handrick C. Laser treatment of hypertrophic scars, keloids, and striae.
Semin Cutan Med Surg 2000; 19(4): 287–92
14. Tanzi EL, Alster TS. Laser treatment of scars. Skin Therapy Lett 2004; 9: 4–7
15. Liu W, Wu X, Gao Z, et al. Remodelling of keloid tissue into normal-looking skin. J Plast Reconstr Aesthet Surg 2008; 61(12): 1553–4
16. Darougheh A, Asilian A, Shariati F. Intralesional triamcinolone alone or in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. Clin Exp Dermatol 2009; 34: 219–23
17. Reish RG, Eriksson E. Scar treatments: preclinical and clinical studies. J Am Coll Surg 2008; 206(4): 719–30
18. Gauglitz GG. Management of keloids and hypertrophic scars: current and emerging options. Clin Cosmet Investig Dermatol 2013; 6: 103–14
1540 Fractional Laser Palomar Medical Technologies
Description Laser scar removal from Palomar® offers a non-invasive solution that uses fractional laser technology to deliver rapid, reliable scar removal with less risk, less pain, and minimal downtime. Our fractional laser technology is the driving power behind our acne and surgical scar removal procedure. We use pulses of laser light to coagulate scar tissue and trigger healthy new tissue to form in clients’ skin. Healing time is minimal, infection risk is eliminated, and little to no pain is felt.
Indications Scar removal for acne scars and surgical scars, all skin types and excellent outcomes
Availability Worldwide Contact
www.palomarmedical.com/treatments/laser-scar-removal.aspx
available study data, the use of 5FU for the treatment of keloids represents a safe approach. Side-effects include pain at the injection site, hyperpigmentation,
skin irritation, and ulceration.
Surgery Surgical excision of keloids without adjuvant therapy, such as post-excisional corticosteroid
MONTH IN PRIME
NEXT injections,
5-fluorouracil, or radiation is associated with high recurrence rates and should therefore be considered with immense caution8
To feature your product contact: rosalind.hill@
informa.com
.
Hypertrophic scars may mature over a 1-year period and may show a decrease of contractures, flattening, softening, and re-pigmentation without any physical manipulation17
. Successful and persisting
Liposuction/Body contouring
removal of hypertrophic scars may be achieved by using Z- or W-plasty, grafts or local skin flaps in order to interrupt the vicious circle between scar tension and consecutive further thickening of the scar due to permanently stimulated ECM production1
.
Gerd G. Gauglitz, MD, MMS, is Head of Department of Aesthetic Dermatology, Department of Dermatology and Allergology, University, Munich, Germany
June 2013 |
prime-journal.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84